Phase II ATEZO-BRAIN: Updated Results With Atezolizumab + Carboplatin/Pemetrexed in Advanced Nonsquamous NSCLC With Untreated Brain Metastases

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
Atezolizumab plus chemotherapy showed favorable safety and promising clinical activity in patients with advanced nonsquamous NSCLC and untreated brain metastases, with a 2-year OS rate of 27.5%.
Format: Microsoft PowerPoint (.ppt)
File Size: 165 KB
Released: June 16, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings